Medpace Holdings, Inc. $MEDP Shares Sold by Swedbank AB

Swedbank AB lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,000 shares of the company’s stock after selling 13,000 shares during the quarter. Swedbank AB owned approximately 0.21% of Medpace worth $29,821,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Wasatch Advisors LP lifted its position in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. lifted its holdings in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after acquiring an additional 121,213 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Medpace by 15.1% in the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after acquiring an additional 81,637 shares during the last quarter. TD Asset Management Inc boosted its stake in Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after acquiring an additional 61,764 shares during the period. Finally, Epoch Investment Partners Inc. grew its holdings in shares of Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after purchasing an additional 45,435 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on MEDP. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 price objective on shares of Medpace in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $490.82.

Medpace Stock Up 0.4%

MEDP stock opened at $572.00 on Friday. The company has a 50-day simple moving average of $578.83 and a 200 day simple moving average of $478.30. The company has a market capitalization of $16.11 billion, a P/E ratio of 40.00, a PEG ratio of 2.16 and a beta of 1.43. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter last year, the company earned $3.01 EPS. Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In other news, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 over the last quarter. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.